Cryptococcus (IDSA 2010): Difference between revisions

From IDWiki
m (Aidan moved page IDSA Cryptococcus 2010 to Cryptococcus (IDSA 2010) without leaving a redirect)
No edit summary
 
Line 1: Line 1:
[https://doi.org/10.1086/649858 Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update]
[https://doi.org/10.1086/649858 Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update]


= Meningoencephalitis =
== Meningoencephalitis ==


== HIV-infected ==
=== HIV-infected ===


* Induction: AmBd 0.7-1 mg/kg/d IV plus flucytosine 100 mg/kg/d po split QID for at least 2 weeks
* Induction: AmBd 0.7-1 mg/kg/d IV plus flucytosine 100 mg/kg/d po split QID for at least 2 weeks
Line 12: Line 12:
** If high
** If high


== Organ transplant ==
=== Organ transplant ===


== Neither HIV infected nor organ transplant ==
=== Neither HIV infected nor organ transplant ===


= Complications =
== Complications ==


= Non-meningeal Cryptococcosis =
== Non-meningeal Cryptococcosis ==


= Special Populations =
== Special Populations ==


[[Category:IDSA guidelines]]
[[Category:IDSA guidelines]]

Latest revision as of 19:33, 15 August 2019

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update

Meningoencephalitis

HIV-infected

  • Induction: AmBd 0.7-1 mg/kg/d IV plus flucytosine 100 mg/kg/d po split QID for at least 2 weeks
    • Can use liposomal AmB 3–4 mg/kg/d IV or ABLC 5 mg/kg/d IV
    • Can continue for 4-6 weeks if high fungal burden or failure to respond
    • Can replace flucytosine with fluconazole 800-1200 mg daily for minimum of 8 weeks if needed
  • Consolidation: fluconazole 400 mg daily for at least 8 weeks
    • If high

Organ transplant

Neither HIV infected nor organ transplant

Complications

Non-meningeal Cryptococcosis

Special Populations